ClinicalTrials.gg
CompletedNCT01904409Updated Oct 23, 2019

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

A Phase 2 interventional study of Placebo and Rifaximin SSD 40 mg IR tablet in Liver Cirrhosis, sponsored by Bausch Health Americas, Inc.. Completed at 121 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing rifaximin in Liver Cirrhosis — 1 open to participants now, 1 under way, none of them phase 3. Rifaximin · Liver Cirrhosis.

Enrollment
Largest of 18
420 · median 57
Started
2013
with 3 others
Phase 2
2 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
1 of 18
Bausch Health Americas, Inc.

Among the 18 studies testing rifaximin in Liver Cirrhosis, this one has the largest enrollment, is one of 4 that started in 2013, is one of 2 in phase 2, and was the 7th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 18 studies testing rifaximin in Liver Cirrhosis is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rifaximin in Liver Cirrhosis, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects with early decompensated liver cirrhosis.

Rifaximin, a non-systemic antibacterial agent, is currently marketed as a 550 mg tablet for the reduction in risk of recurrent overt hepatic encephalopathy, a complication of liver cirrhosis. The rifaximin SSD tablet was formulated to maximize the efficacy of rifaximin.

Subjects will receive 1 of 5 doses of rifaximin SSD tablets or placebo tablets every day for 24 weeks.

03

Conditions studied

  • Liver Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of liver cirrhosis and documented ascites.
  • Model End Stage Liver Disease (MELD) score of at least 12, MELD Na of at least 12, or B (score of 7 - 9).
  • If applicable, has a close family or other personal contacts who can provide continuing oversight to the patient and will be available to the patient during the conduct of the trial.
  • If female of , have a negative serum pregnancy test at study start and agree to use an acceptable method of during the study.

Exclusion criteria

Exclusion Criteria:

  • History of a major psychiatric disorder including uncontrolled major depression or controlled or uncontrolled psychoses within the past 24 months prior to study start.
  • History of alcohol abuse or substance abuse within the past 3 months prior to study start.
  • Documented cholestatic liver disease such as primary sclerosing cholangitis.
  • Had prophylactic variceal banding within 2 weeks or is scheduled to undergo prophylactic banding during the study.
  • Diagnosed with an infection for which the patient is currently taking oral or parenteral antibiotics.
  • Significant hypovolemia, or any electrolyte abnormality that can affect mental function (eg, serum sodium \< 125 mEq/L, serum calcium > 10 mg/dL).
  • Severe hypokalemia, defined as serum potassium concentration \< 2.5 mEq/L.
  • Anemic, defined as concentration ≤ 8 g/dL.
  • Renal insufficiency with a creatinine of ≥ 1.5 mg/dL.
  • Presence of intestinal obstruction or inflammatory bowel disease.
  • Uncontrolled Type 1 or Type 2 diabetes.
  • History of seizure disorders.
  • Unstable cardiovascular or pulmonary disease, categorized by a worsening in the disease condition that requires a change in treatment or medical care within 30 days of study start.
  • Active within the last 5 years (exceptions: basal cell carcinomas of the skin, or if female, in situ cervical carcinoma that has been surgically excised).
  • Has hepatocellular carcinoma.
  • Known , varicella, herpes zoster, or other severe viral infection within 6 weeks of study start.
  • Positive stool test for Yersinia enterocolitica, Campylobacter jejuni, Salmonella, Shigella, ovum and parasites, and/or Clostridium difficile (C. difficile); determined during the screening period prior to study start.
  • History of tuberculosis infection and/or has received treatment for a tuberculosis infection.
  • History of to rifaximin, rifampin, rifamycin antimicrobial agents, or any of the components of rifaximin soluble solid dispersion.
  • Used any product or device, or participated in another research study within 30 days prior to study start.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo tablets once daily.

    Drug: Placebo

  • Experimental
    Rifaximin SSD 40 mg IR tablet

    Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.

    Drug: Rifaximin SSD 40 mg IR tablet

  • Experimental
    Rifaximin SSD 80 mg IR tablet

    Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.

    Drug: Rifaximin SSD 80 mg IR tablet

  • Experimental
    Rifaximin SSD 40 mg SER tablet

    Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.

    Drug: Rifaximin SSD 40 mg SER tablet

  • Experimental
    Rifaximin SSD 80 mg SER tablet

    Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.

    Drug: Rifaximin SSD 80 mg SER tablet

  • Experimental
    Rifaximin SSD 80mgIR/80mgSER tablet

    Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.

    Drug: Rifaximin SSD 80mgIR/80mgSER tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Time to all-cause mortality or hospitalization that is attributable to complications of liver disease.

    The primary outcome measure will evaluate the time from start of the treatment period to death due to any cause (all-cause mortality) or hospitalization due to complications of liver disease for each patient during the 24-week treatment period.

    Time frame: Weeks 1 through 24

Secondary outcomes

  1. Overall hospitalization rate due to each complication of liver disease or all-cause mortality over the 24-week treatment period.

    This outcome measure will determine the rate of hospitalization (percentage of patients who are hospitalized) due to each complication of liver disease or all-cause mortality over the 24-week treatment period.

    Time frame: Weeks 1 through 24

  2. Pharmacokinetics of rifaximin and its metabolite.

    This outcome will measure the plasma levels of rifaximin and its metabolite (25-desacetyl rifaximin) for each patient during the 24-week treatment period.

    Time frame: Weeks 1 through 24

  3. Incidence of treatment-emergent adverse events.

    This outcome will evaluate the incidence of treatment-emergent adverse events (percentage of patients who experience adverse events following the start of the treatment period).

    Time frame: Weeks 1 through 24

  4. Change in clinical laboratory parameters.

    This outcome will measure the changes in each patient's clinical laboratory test results during the treatment period.

    Time frame: Weeks 1 through 24

  5. Changes in electrocardiogram measurements

    This outcome will measure the changes in measurements obtained from 12-lead electrocardiograms for each patient during the treatment period.

    Time frame: Weeks 1 through 24

  6. Changes in indices of health outcomes

    This outcome will evaluate each patient's responses on questionnaires that assess health status.

    Time frame: Weeks, 4, 8, 12, 16, and 24

07

Study locations

121 sites
  • Salix Investigative Site
    Birmingham, Alabama 35294, United States
  • Salix Investigative Site
    Dothan, Alabama 36305, United States
  • Salix Investigative Site
    Mobile, Alabama 36617, United States
  • Salix Investigative Site
    Tucson, Arizona 85712, United States
  • Salix Investigational Site
    Artesia, California 90701, United States
  • Salix Investigational Site
    Bakersfield, California 93301, United States
  • Salix Investigational Site
    Chula Vista, California 91910, United States
  • Salix Investigational Site
    Coronado, California 92118, United States
  • Salix Investigational Site
    Costa Mesa, California 92626, United States
  • Salix Investigative Site
    Fresno, California 93701, United States
  • Salix Investigational Site
    La Jolla, California 92037, United States
  • Salix Investigative Site
    Los Angeles, California 90033, United States
  • Salix Investigational Site
    Monterey, California 93940, United States
  • Salix Investigational Site
    Riverside, California 92377, United States
  • Salix Investigational Site
    San Diego, California 92114, United States
  • Salix Investigational Site
    Ventura, California 93003, United States
  • Salix Investigational Site
    Englewood, Colorado 80113, United States
  • Salix Investigational Site
    Littleton, Colorado 80120, United States
  • Salix Investigational Site
    Bristol, Connecticut 06035, United States
  • Salix Investigational Site
    New Haven, Connecticut 06520, United States
  • Salix Investigational Site
    Waterbury, Connecticut 06708, United States
  • Salix Investigational Site
    Coral Gables, Florida 33134, United States
  • Salix Investigational Site
    Gainesville, Florida 32610, United States
  • Salix Investigative Site
    Hialeah, Florida 33012, United States
  • Salix Investigational Site
    Hialeah, Florida 33016, United States
  • Salix Investigational Site
    Hollywood, Florida 33021, United States
  • Salix Investigative Site
    Inverness, Florida 34452, United States
  • Salix Investigational Site
    Lake Worth, Florida 33449, United States
  • Salix Investigative Site
    Largo, Florida 33777, United States
  • Salix Investigative Site
    Maitland, Florida 32751, United States
  • Salix Investigational Site
    Miami Springs, Florida 33166, United States
  • Salix Investigational Site
    Miami, Florida 33030, United States
  • Salix Investigational Site
    Miami, Florida 33126, United States
  • Salix Investigational Site
    Miami, Florida 33136, United States
  • Salix Investigational Site
    New Port Richey, Florida 34653, United States
  • Salix Investigative Site
    Orlando, Florida 32824, United States
  • Salix Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Salix Investigational Site
    Port Orange, Florida 32127, United States
  • Salix Investigational Site
    Saint Cloud, Florida 34769, United States
  • Salix Investigational Site
    Tamarac, Florida 33319, United States
  • Salix Investigational Site
    Atlanta, Georgia 30309, United States
  • Salix Investigative Site
    Atlanta, Georgia 30342, United States
  • Salix Investigative Site
    Decatur, Georgia 30033, United States
  • Salix Investigational Site
    Macon, Georgia 31201, United States
  • Salix Investigative Site
    Chicago, Illinois 60612, United States
  • Salix Investigative Site
    Maywood, Illinois 75390, United States
  • Salix Investigational Site
    Evansville, Indiana 47714, United States
  • Salix Investigational Site
    Indianapolis, Indiana 46202, United States
  • Salix Investigative Site
    Iowa City, Iowa 52242, United States
  • Salix Investigational Site
    Bowling Green, Kentucky 42101, United States
  • Salix Investigational Site
    Bastrop, Louisiana 71220, United States
  • Salix Investigational Site
    Monroe, Louisiana 71201, United States
  • Salix Investigational Site
    New Orleans, Louisiana 70112, United States
  • Salix Investigational Site
    Shreveport, Louisiana 71103, United States
  • Salix Investigational Site
    Annapolis, Maryland 21401, United States
  • Salix Investigational Site
    Baltimore, Maryland 21202, United States
  • Salix Investigational Site
    Baltimore, Maryland 21228, United States
  • Salix Investigational Site
    Chevy Chase, Maryland 20815, United States
  • Salix Investigational Site
    Hagerstown, Maryland 21743, United States
  • Salix Investigational Site
    Boston, Massachusetts 02114, United States
  • Salix Investigational Site
    Boston, Massachusetts 02115, United States
  • Salix Investigational Site
    Brockton, Massachusetts 02302, United States
  • Salix Investigational Site
    Springfield, Massachusetts 01105, United States
  • Salix Investigative Site
    Chesterfield, Michigan 48047, United States
  • Salix Investigational Site
    Wyoming, Michigan 49519, United States
  • Salix Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Salix Investigative Site
    Tupelo, Mississippi 38801, United States
  • Salix Investigational Site
    Kansas City, Missouri 64131, United States
  • Salix Investigative Site
    Saint Louis, Missouri 63110, United States
  • Salix Investigational Site
    Marlton, New Jersey 08053, United States
  • Salix Investigational Site
    New Brunswick, New Jersey 07102, United States
  • Salix Investigative Site
    Bronx, New York 10467, United States
  • Salix Investigative Site
    Brooklyn, New York 60153, United States
  • Salix Investigational Site
    Flushing, New York 11040, United States
  • Salix Investigational Site
    New York, New York 10016, United States
  • Salix Investigational Site
    New York, New York 10032, United States
  • Salix Investigational Site
    Rochester, New York 14642, United States
  • Salix Investigational Site
    Asheville, North Carolina 28801, United States
  • Salix Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • Salix Investigative Site
    Charlotte, North Carolina 28204, United States
  • Salix Investigational Site
    Charlotte, North Carolina 28207, United States
  • Salix Investigational Site
    Fayetteville, North Carolina 28304, United States
  • Salix Investigational Site
    Wilmington, North Carolina 28403, United States
  • Salix Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Salix Investigative Site
    Cincinnati, Ohio 45224, United States
  • Salix Investigational Site
    Cincinnati, Ohio 45249, United States
  • Salix Investigational Site
    Cleveland, Ohio 44195, United States
  • Salix Investigative Site
    Dayton, Ohio 45415, United States
  • Salix Investigational Site
    Mentor, Ohio 44060, United States
  • Salix Investigational Site
    Portland, Oregon 97210, United States
  • Salix Investigative Site
    Bristol, Tennessee 37620, United States
  • Salix Investigational Site
    Chattanooga, Tennessee 37421, United States
  • Salix Investigational Site
    Nashville, Tennessee 37205, United States
  • Salix Investigational Site
    Nashville, Tennessee 37211, United States
  • Salix Investigative Site
    Arlington, Texas 76012, United States
  • Salix Investigational Site
    Austin, Texas 78705, United States
  • Salix Investigational Site
    Dallas, Texas 75203, United States
  • Salix Investigational Site
    Dallas, Texas 75246, United States
  • Salix Investigative Site
    Dallas, Texas 75390, United States
  • Salix Investigational Site
    Fort Worth, Texas 76104, United States

Showing the first 100 of 121 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bajaj JS, Hassanein TI, Pyrsopoulos NT, Sanyal AJ, Rahimi RS, Heimanson Z, Israel RJ, Rockey DC. Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials. Clin Gastroenterol Hepatol. 2023 Mar;21(3):723-731.e9. doi: 10.1016/j.cgh.2022.05.042. Epub 2022 Jun 22. PubMed 35750249 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jun 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2013
First posted
Jul 22, 2013
Start
Jun 2013
Primary completionActual
Jun 2015
CompletionActual
Jul 2015
Results delay requested
Dec 13, 2017
Last update
Oct 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01904409
Responsible party
Sponsor
First posted
Jul 22, 2013
Start date
Jun 2013
Primary completion
Jun 2015
Completion
Jul 2015
Last update
Oct 23, 2019

Study contacts

James Joffrion
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion